![]() |
|
以作者查詢圖書館館藏 、以作者查詢臺灣博碩士 、以作者查詢全國書目 、勘誤回報 、線上人數:64 、訪客IP:18.217.204.181
姓名 徐瑞靜(Jui-Ching Hsu) 查詢紙本館藏 畢業系所 化學學系 論文名稱 一、石膽酸衍生物合成: 香豆素、NBD及其它官能基之石膽酸類似物做為有效的抗癌化合物和生物探針 二、合成Malyngamide 1和Isomalyngamide A類似物成為唾液酸轉移酶的抑制劑:具鏈長及官能基依賴性之結構活性關係研究
((1)Synthesis of modified lithocholic acids: coumarin, nitro-2,1,3-benzoxadiazole and other functional groups as effective anticancer agents and biological probes.(2)Analogues of Malyngamide 1 and Isomalyngamide A as inhibitors of sialyltransferases:A structure activity relationship study of chain-length and functional dependence. )相關論文 檔案 [Endnote RIS 格式]
[Bibtex 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
[檢視]
[下載]
- 本電子論文使用權限為同意立即開放。
- 已達開放權限電子全文僅授權使用者為學術研究之目的,進行個人非營利性質之檢索、閱讀、列印。
- 請遵守中華民國著作權法之相關規定,切勿任意重製、散佈、改作、轉貼、播送,以免觸法。
摘要(中) 第一部分:
石膽酸衍生物合成: 香豆素、NBD及其它官能基之石膽酸類似物做為有效的抗癌化合物和生物探針
唾液酸轉移酶的過度表現是細胞組織的生物過程,在許多生理上和病理上有扮演重要的角色,例如:細胞間的黏附、癌症轉移及感染息息相關,所以本實驗室嘗試去改善由石膽酸為骨架,所衍生的唾液酸轉移酶抑制劑,找到一系列效果更好的抑制劑。其中,首度合成出石膽酸結合香豆素(coumarin)衍生物及一些疏水性基團和NBD (7- Nitro-2,1,3-benzoxadiazole)的新型複合物,找到可穿透細胞膜的化合物5-25,其中還有些對唾液酸轉移酶的抑制效果IC50值已經達到接近nM的等級;在乳癌癌細胞實驗中,以20 μM的濃度也具有微量4~40%的毒殺效果,且化合物25更進一步證明可以有效抑制癌細胞的轉移,將來在癌症治療中可與化療藥物合併或單獨使用,而香豆素衍生物及NBD具有螢光的性質可進一步作為酵素螢光探針,幫助了解唾液酸轉移酶在細胞中的分佈。
本實驗室並進一步發展具有胺基長鏈的NBD石膽酸化合物32和36,期望將來可以結合在奈米粒子上用來抓取細胞中或組織內的唾液酸轉移酶及相關蛋白,可用來研究此類藥物對細胞中各種蛋白的作用,並幫助了解唾液酸轉移酶的作用機制。
第二部分:
合成Malyngamide 1和Isomalyngamide A類似物成為唾液酸轉移酶的抑制劑:具鏈長及官能基依賴性之結構活性關係研究
Malyngamide 1和Isomalyngamide A是海藻中提煉出來的天然物,其對於唾液酸轉移酶的抑制效果大約到66 μM、77 μM的等級;在乳癌癌細胞實驗中,則具有IC50 = 12.7、2.8 μM很好的毒殺效果,所以合成出一系列相關的結構,期望找到其活性作用的藥效基團並做相關結構活性的探討。摘要(英) Part I:
Synthesis of modified lithocholic acids: coumarin, nitro-2,1,3-benzoxadiazole and other functional groups as effective anticancer agents and biological probes.
Overexpression of sialyltransferase is a vital biological process, which plays a role in various physiological and pathological events, such as cell-cell adhesion, tumor cell metastasis and invasions. To increase the inhibitory potency of sialyltransferase, we prepared the coumarin, NBD (7-nitro-2,1,3-benzoxadiazole) and other functional derivatives of lithocholic acid based on our previous studies. Some of these compounds, 5-25, represent the first examples of nanomolar range sialyltransferase inhibitors with cell permeability which had been demonstrated by the experiment of wound healing and the detection of fluorescence imaging of cells incubated with coumarin or NBD derivative of lithocholic acid. Except the property of antimetastasis in wound healing assay, compounds 5-25 also slightly displayed inhibition of the proliferation of breast cancer cells with the inhibitory percentages ranging from 4~40% under the compound dose at 20 ?M.
To investigate the capability of lithocholic acid derivatives attracting the sialyltransferase proteins in vitro and in vivo, nanoparticle-based sialyltransferase inhibitors, 32-36, were prepared to tackle this problem.
Part II:
Analogues of Malyngamide 1 and Isomalyngamide A as inhibitors of sialyltransferases: A structure activity relationship study of chain-length and functional dependence.
Malyngamide 1 and Isomalyngamide A are natural products from Marine and display the significant cytotoxic activity against breast cancer cells at the low micromolar level (IC50 = 12.7 and 2.8 μM). Meanwhile, one of them also inhibited alpha-2,3-sialyltransferase activity at micromolar concentration (IC50 = 66 μM). To find out the pharmacophore, several substructures of malyngamide 1 were synthesized, and their inhibitory properties of sialyltransferase and cytotoxic activities against breast cancer cells were also studied.關鍵字(中) ★ 石膽酸
★ 唾液酸轉移酶關鍵字(英) ★ sialyltransferase
★ lithocholic acid論文目次 目 錄
中英文摘要
謝誌
一、唾液酸轉移酶抑制劑設計……………………………………1
1. 導論…………………………………………………………1
1.1 唾液酸的結構與功能…………………………………1
1.2 唾液酸轉移酶在生物上的功能………………………2
1.3 唾液酸轉移酶抑制劑的設計…………………………4
1.3.1 以donor結構為基礎所設計的抑制劑………………4
1.3.2 過渡狀態類似物的抑制劑……………………………5
1.3.3 醣受體類似物的抑制劑………………………………6
1.4 石膽酸衍生物作為抑制劑……………………………8
1.4.1 石膽酸介紹…………………………………………8
1.4.2 已知石膽酸衍生物作為抑制劑……………………9
1.5 藥物香豆素Coumarin的介紹………………………9
2. 結果與討論…………………………………………………10
2.1 合成石膽酸-香豆素衍生物………………………10
2.1.1 石膽酸-香豆素衍生物的實驗動機………………10
2.1.2 合成石膽酸-香豆素衍生物………………………11
2.2 合成石膽酸-其他官能基…………………………16
2.2.1 石膽酸-其他官能基的實驗動機…………………16
2.2.2 合成石膽酸-其他官能基………………………16
2.3 合成石膽酸-NBD及分子探針……………………19
2.3.1 石膽酸-NBD及分子探針的實驗動機……………19
2.3.2 合成石膽酸-NBD及分子探針…………………20
2.4 生物活性討論……………………………………26
2.5 結論………………………………………………31
二、合成Malyngamide 1 和 Isomalyngamide A類似物……32
3. 導論………………………………………………………32
4. 結果與討論………………………………………………33
4.1 Malyngamide 1 和 Isomalyngamide A類似物………33
4.1.1 Malyngamide 1 和 Isomalyngamide A類似物的實驗動機………………………………………………33
4.1.2 合成Malyngamide 1 和 Isomalyngamide A類似物33
4.2 生物活性討論…………………………………………36
4.3 結論……………………………………………………37
三、實驗步驟與數據………………………………………………38
5. 實驗儀器……………………………………………………38
6. 實驗藥品………………………………………………………40
7. 一般實驗方法…………………………………………………43
四、參考文獻………………………………………………………75
五、光譜資料………………………………………………………77參考文獻 四、 參考文獻
1. Bertozzi, C. R.; Kiessling, L. L. Science 2001, 291, 2357.
2. Kiefel, M. J.; von Itzstein, M. Chem. Rev. 2002, 102, 471.
3. Abraham Rosenbergy Biology of the Sialic acid, 1995
4. Cecilia P C Chiu, Andrew G Watts, Luke L Lairson, Michel Gilbert, Daniel Lim, Warren W Wakarchuk, Stephen G Withers& Natalie C J Strynadka , Nat. Struct. Mol. Biol. 2004, 11, 163.
5. Hildebrandt, H.; Becker, C.; Gluer, S.; Rosner, H.; GerardySchahn, R.; Rahmann, H. Cancer Res. 1998, 58, 779.
6. Geßner, P.; Riedl, S.; Quentmaier, A.; Kemmer, W. Cancer Lett. 1993, 75, 143.
7. Burchell, J.; Poulsom, R.; Hanby, A.; Whitehouse, C.; Clausen, H.; Miles, D.; Taylor-Papadimitriou, J. Glycobiology 1999, 9, 1307.
8. Dall’Olio, F.; Malagolini, N.; di Stefano, G.; Minni, F.; Marrano, D.; Serafini-Cessi, F. Int. J. Cancer 1989, 44, 434.
9. Dimitroff, C. J.; Pera, P.; Dall’Olio, F.; Matta, K. L.; Chandrasekaran, E. V.; Lau, J. T.; Bernacki, R. J. Biochem. Biophys. Res. Commun. 1999, 256, 631.
10. Sottocornola, E.; Colombo, I.; Vergani, V.; Taraboletti, G.; Berra, B. Invasion Metastasis 1998, 18, 142.
11. Wang, X.; Zhang, L. -H.; Ye, X. -S. Med. Res. Rev. 2003, 23, 32.
12. Hatanaka, Y.; Kaneoka, Y. Chem. Absir. 1993, 119, 49839.
13. Christoph, S.; Bernd, M.; Schmidt, R. R. Glycoconj. J. 1998, 15, 345.
14. Muller, B.; Mardn, T. J.; Schaub, C.; Schmidt, R. R. Tetrahedron Lett. 1998, 39, 509.
15. Whalen, L. J.; McEvoy, K. A.; Halcomb, R. L. Bioorg. Med. Chem. Lett. 2003, 13, 301.
16. Horenstein, B. A.; Bruner, M. J. Am. Chem. Soc. 1996, 118, 10371.
17. Horenstein, B. A. J. Am. Chem. Soc. 1997, 119, 1101.
18. Horenstein, B. A.; Bruner, M. J. Am. Chem. Soc. 1998, 120, 1357.
19. Bruner, M.; Horenstein, B. A. Biochemistry 1998, 37, 289.
20. Bruner, M.; Horenstein, B. A. Biochemistry 2000, 39, 2261.
21. Muller, B.; Schaub, C.; Schmidt, R. R. Angew. Chem. Int. Ed. 1998, 37, 2893.
22. Amann, F.; Schaub, C.; Muller, B.; Schmidt R. R. Chem. Eur. J. 1998, 4, 1106.
23. Schworer, R.; Schmidt, R. R. J. Am. Chem. Soc. 2002, 124, 1632.
24. Sun, H. B.; Yang, J. S.; Amaral, K. E.; Horenstein, B. A. Tetrahedron Lett. 2001, 42, 2451.
25. Kajihara, Y.; Kodama, H.; Wakabayashi, T.; Sato, K.; Hashimoto, H. Carbohydr. Res. 1993, 247, 179.
26. Wu, C. Y.; Hsu, C. C.; Chen, S. T.; Tsai, Y. C. Biochem. Biophys. Res. Commun. 2001, 284(2), 466.
27. Chang, K.-H.; Lee, L.; Chen, J.; Li, W.-S. Chem. Commun. 2006, 629.
28. Nelson, D. L.; Michael, M. Cox : Lehninger Principles of Biochemistry 4th Ed.
29. Tochtrop, G. P.; DeKoster, G. T.; Cistola, D. P.; Covey, D. F. J. Org. Chem. 2002, 67, 6764.
30. Palmeira, C. M.; Anabela, P. R. C.M. Palmeria, A. P. Rolo / Toxicology 2004, 203, 1.
31. Mizushina, Y.; Kasai, N.; Sugawara, F.; Yoshida, H.; Sakaguchi, K. J. Biochem. 2001, 130, 657.
32. Ogawa, A.; Murate, T.; Suzuki, M.; Nimura, Y.; Yoshida, S. J. Cancer Res. 1998, 89, 1154.
33. Bernstein, H.; Bernstein, C.; Payne, C. M.; Garewal, H. Mutat. Res.-Rev. Mutat. Res. 2005, 589, 47.
34. Trenor, S. R.; Shultz, A. R.; Love, B. J.; Long, T. E.Chem.Rev. 2004, 104, 3059.
35. Brubaker, A. N.; Deruiter, J.; Whitmer, W. L., Synthesis and Rat Lens Aldose Reductase Inhibitory Activity of Some Benzopyran-2-Ones. Journal of Medicinal Chemistry 1986, 29(6), 1094.
36. Sethna, S.; Phadke, R., The Pechmann Reaction. Organic Reactions 1953, 7, 1.
37. Liu, X.; Ma, Z.; Xing, J.; Liu, H. J. Magn. Magn. Mater. 2004, 270, 1.
38. Lin, P.-C.; Chou, P.-H.; Chen, S.-H.; Liao, H.-K.; Wang, K.-Y.; Chen, Y.-J.; Lin, C.-C. Small 2006, 4, 485.
39. Lin, P.-C.; Tseng, M.-C.; Su, A.-K.; Chen, Y.-J.; Lin, C.-C. Anal. Chem. 2007, 79, 3401.
40. Burja, A. M.; Banaigs, B.; Abou-Mansour, E.; Burgess, J. G.; Wright, P. C. Tetrahedron 2001, 57, 9347.
41. Kan, Y.; Sakamoto, B.; Fujita, T.; Nagai,H. J. Nat.Prod. 2000,63,1599.
42. Cardellina II, J. H.; Marner, F.-J.; Moore, R. E. J. Am. Chem. Soc. 1979, 101, 240.
43. 柳公政,國立台灣師範大學,碩士論文,2007。指導教授 李文山、李文仁
(Wen-Shan Li、Wen-Ren Li)審核日期 2008-7-22 推文 plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
網路書籤 Google bookmarks
del.icio.us
hemidemi
myshare